USPTO 2015–2025 USPTO PatentsView US Corporation

CorneaGen

USPTO PatentsView assignee record - 13 granted patents across 7 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Corneagen ranks #20,964 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 7 technology areas.

#20,964
of 49,997 US assignees by volume
Top 39%
by Innovation Score (38.9/100)
16.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R20964 · US Corporation #20,964 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 13 grants
  • MID-PACK #20,964/49,997
  • PHOTO-FINISH Converter Manufactur…
  • CPC-NARROW A61F · 7 areas
  • INNOV-THIN 38.9/100
  • CLAIMS-RICH 16.3 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2024 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Converter Manufacturing, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Corneagen’s 38.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Corneagen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Corneagen's Innovation Score is 38.9/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Corneagen?

Each dot is one of Corneagen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Corneagen’s own 16.3 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Corneagen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 12.912.91313.1 510152025 Granted patents (volume) Avg claims / patent Converter Manufacturing, LLC - 13, 20.46Converter Manufac…Cooper Standard GmbH - 13, 15.23Cooper StandardCore Scientific Operating Company - 13, 18.77Core Scientific O…CoreLED Systems, LLC - 13, 10.77Coreled SystemsCosmo Lighting Inc. - 13, 9.54Cosmo LightingCouchbase, Inc. - 13, 19.77CouchbaseCranfield University - 13, 17.31Cranfield Univers…Cristal USA, Inc. - 13, 15.69Cristal USACorneaGen - 13, 16.31Corneagen
Corneagen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Corneagen's grants concentrate

CorneaGen is a focused PatentsView assignee: 7 CPC subclasses with 84.6% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2020. By volume, Corneagen sits between Converter Manufacturing, LLC and Cristal USA, Inc..

Corneagen's three-year grant acceleration

CorneaGen shows 8 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at CorneaGen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows CorneaGen holds 13 patents at rank #20,973, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near CorneaGen

By rank, the assignees closest to #20,973 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in CorneaGen's primary technology class.

Corneagen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 39% higher than 61% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 2020202120232024 4
USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
CorneaGen patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 7.7%
2021 4 30.8%
2023 4 30.8%
2024 4 30.8%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

CorneaGen's patent record in context - here's where to go next.

  • CorneaGen's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 84.6% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #20,964 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare CorneaGen against Converter Manufacturing, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 38.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.